MeiraGTx (MGTX) Stock Price, News & Analysis

Company Overview

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders. MeiraGTx has established an end-to-end platform encompassing vector design, process development, and manufacturing scale-up, with capabilities housed in facilities across the United Kingdom and the United States. This integrated approach aims to accelerate the transition from preclinical research to clinical trials and, ultimately, patient access.

MeiraGTx completed its initial public offering on the Nasdaq in April 2018 and operates research laboratories in London alongside a manufacturing and clinical operations center in the New York metropolitan area. The company’s leadership team comprises industry veterans with extensive experience in gene therapy development, regulatory affairs and commercialization. MeiraGTx continues to advance its clinical programs in collaboration with academic institutions and contract research organizations, targeting global patient populations in need of novel therapeutic options.

Key Stats

• Today's Range: $13.76 to $14.15
• 50-Day Range: $11.62 to $14.97
• 52-Week Range: $6.62 to $15.35
• Volume: 824,112 shs
• Average Volume: 684,186 shs
• Market Capitalization: $1.34 billion
• P/E Ratio: 19.68
• Dividend Yield: N/A
• Price Target: $26.17
• Consensus Rating: Buy

MeiraGTx Stock Analysis - MarketRank™

MeiraGTx scored higher than 83% of companies evaluated by MarketBeat, and ranked 101st out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

MeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

MeiraGTx has a consensus price target of $26.17, representing about 87.3% upside from its current price of $13.97.

Amount of Analyst Coverage

MeiraGTx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MeiraGTx are expected to decrease in the coming year, from $0.30 to ($2.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MeiraGTx is 19.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.90.

Price to Earnings Ratio vs. Sector

The P/E ratio of MeiraGTx is 19.68, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.28.

Price to Book Value per Share Ratio

MeiraGTx has a P/B Ratio of 6.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.20% of the float of MeiraGTx has been sold short.

Short Interest Ratio / Days to Cover

MeiraGTx has a short interest ratio ("days to cover") of 8.07.

Change versus previous month

Short interest in MeiraGTx has recently decreased by 4.08%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MeiraGTx does not currently pay a dividend.

Dividend Growth

MeiraGTx does not have a long track record of dividend growth.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.41

News Sentiment

MeiraGTx has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for MeiraGTx this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for MGTX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

5 people have added MeiraGTx to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,969,233.00 in company stock.

Percentage Held by Insiders

7.40% of the stock of MeiraGTx is held by insiders.

Percentage Held by Institutions

67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/04/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MGTX
• CIK: 1735438
• Web: www.meiragtx.com
• Phone: (646) 860-7985
• Fax: N/A
• Employees: 300
• Year Founded: 2015

Price Target and Rating

• Average Price Target for MeiraGTx: $26.17
• High Price Target: $35.00
• Low Price Target: $16.00
• Potential Upside/Downside: +87.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.71
• Trailing P/E Ratio: 19.68
• Forward P/E Ratio: 46.57
• P/E Growth: N/A
• Net Income: -$114.20 million
• Net Margins: 19.87%
• Pretax Margin: 20.45%
• Return on Equity: 283.85%
• Return on Assets: 29.39%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 3.76
• Quick Ratio: 3.76

Sales & Book Value

• Annual Sales: $81.39 million
• Price / Sales: 16.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.25 per share
• Price / Book: 6.21

Miscellaneous

• Outstanding Shares: 96,040,000
• Free Float: 88,936,000
• Market Cap: $1.34 billion
• Optionable: Optionable
• Beta: 1.27